Oppenheimer Asset Management Inc. Has $43.59 Million Stock Holdings in Zoetis Inc. $ZTS

Oppenheimer Asset Management Inc. lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.4% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 279,505 shares of the company’s stock after buying an additional 3,771 shares during the period. Oppenheimer Asset Management Inc. owned about 0.06% of Zoetis worth $43,589,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after buying an additional 189,287 shares in the last quarter. Polen Capital Management LLC grew its position in Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the last quarter. Northern Trust Corp grew its position in Zoetis by 1.2% during the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after acquiring an additional 109,791 shares during the last quarter. Finally, Brown Advisory Inc. grew its position in Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after acquiring an additional 312,746 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 0.2%

NYSE ZTS opened at $146.14 on Friday. The business’s 50-day moving average price is $148.18 and its two-hundred day moving average price is $153.57. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $184.40. The firm has a market capitalization of $64.77 billion, a PE ratio of 25.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 EPS. The business’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis’s dividend payout ratio is presently 34.42%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ZTS. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partnrs lowered Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Friday. Finally, Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Four analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.